RÉSUMÉ
La tomografía de coherencia óptica (OCT) es una técnica de imagen endovascular con elevada resolución espacial que permite evaluar las diferentes estructuras que componen la pared de las arterias coronarias, caracterizar morfológicamente la placa aterosclerótica y establecer el mecanismo fisiopatológico subyacente en los síndromes coronarios agudos (SCA). Se presenta el caso clínico de un paciente con infarto agudo de miocardio, donde la OCT evidenció que la reducción de la luz arterial estaba determinada principalmente por la presencia de trombo, a la vez que demostró una disrupción endotelial (ruptura de placa) como mecanismo fisiopatológico subyacente. Se adoptó una estrategia invasivo-conservadora, donde finalmente no se implantó stent. La información surgida de la OCT en este caso particular fue fundamental en la toma de decisiones.
Optical coherence tomography (OCT) is an endovascular imaging technique with high spatial resolution. It allows to evaluate the different structures that compose coronary arteries' wall, morphologically characterize atherosclerotic plaques and establish the underlying pathophysiological mechanism in acute coronary syndromes (ACS). The case of a patient with acute myocardial infarction is presented, in which OCT showed that the reduction of arterial lumen was determined mainly by the presence of thrombus, while also demonstrated endothelial disruption (plaque rupture) as the underlying pathophysiological mechanism. An invasive-conservative strategy was adopted and finally stent was not implanted. The information that emerged from the OCT in this particular case was fundamental in decision-making.
A tomografia de coerência óptica (OCT) é uma técnica de imagem endovascular com alta resolução espacial que permite a avaliação das diferentes estruturas que compõem a parede das artérias coronárias, a caracterização morfológica da placa aterosclerótica e o estabelecimento do mecanismo fisiopatológico subjacente de síndrome coronariana aguda (SCA). Apresentamos o caso clínico de um paciente com enfarte agudo do miocárdio, onde a OCT mostrou que a redução do lúmen arterial foi determinada principalmente pela presença de trombo, ao mesmo tempo que demonstrou uma ruptura endotelial (ruptura da placa) como causa fisiopatológica subjacente. Adotou-se uma estratégia invasiva-conservadora, onde finalmente o stent não foi implantado. As informações obtidas da OCT neste caso específico foram fundamentais na tomada de decisão.
Sujet(s)
Humains , Mâle , Adulte d'âge moyen , Thrombose coronarienne/imagerie diagnostique , Tomographie par cohérence optique , Infarctus du myocarde/imagerie diagnostique , Thrombose coronarienne/traitement médicamenteux , Cinéangiographie , Sténose coronarienne/traitement médicamenteux , Sténose coronarienne/imagerie diagnostique , Plaque d'athérosclérose/traitement médicamenteux , Plaque d'athérosclérose/imagerie diagnostique , Infarctus du myocarde/physiopathologie , Infarctus du myocarde/traitement médicamenteux , Infarctus du myocarde/thérapieRÉSUMÉ
Abstract The universal definition of myocardial infarction (MI) provides five subtypes of acute myocardial infarction (AMI). We present an interesting case of a type 2 myocardial infarction caused by the dilation of the left thoracic stomach.
Sujet(s)
Humains , Mâle , Sujet âgé , Estomac/chirurgie , Dilatation gastrique/étiologie , Anastomose chirurgicale/effets indésirables , Oesophage/chirurgie , Infarctus du myocarde inférieur/étiologie , Dilatation gastrique/traitement médicamenteux , Dilatation gastrique/imagerie diagnostique , Benzamides/usage thérapeutique , Agents gastro-intestinaux/usage thérapeutique , Morpholines/usage thérapeutique , Maladie aigüe , Oesophagectomie/méthodes , Gastroparésie/étiologie , Gastroparésie/traitement médicamenteux , Gastroparésie/imagerie diagnostique , Sténose coronarienne/étiologie , Sténose coronarienne/traitement médicamenteux , Sténose coronarienne/imagerie diagnostique , Électrocardiographie , Oesophage/imagerie diagnostique , Infarctus du myocarde inférieur/diagnosticRÉSUMÉ
This was designed to assess the outcomes of side branch (SB) stenosis after implantation of three drug-eluting stents (DES). From 2,645 patients in the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Trial, 788 patients had 923 bifurcation lesions with SB > or = 1.5 mm were included. SB was treated in 150 lesions, including 35 (3.8%) receiving SB stenting. Of untreated SB with baseline stenosis < 50%, the incidences of periprocedural SB compromise was similar in the zotarolimus (15.8%), sirolimus (17.2%), and paclitaxel (16.6%) stent groups (P = 0.92). At follow-up angiography, delayed SB compromise occurred in 13.9%, 3.2%, and 9.4% (P = 0.010) of these groups. When classified into four groups (< 50%, 50%-70%, 70%-99%, and 100%), 9.0% of untreated SB were worsened, whereas improvement and stationary were observed in 9.6% and 81.4%. In a multivariable logistic regression model, main branch (MB) stenosis at follow-up (%) was the only independent predictor of SB stenosis worsening (odds ratio, 1.03; 95% confidence interval, 1.01-1.04; P < 0.001). After MB stenting in bifurcation lesions, a minority of SB appears to worsen. DES with strong anti-restenotic efficacy may help maintain SB patency.
Sujet(s)
Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Maladie aigüe , Vaisseaux sanguins/physiopathologie , Agents cardiovasculaires/usage thérapeutique , Coronarographie , Sténose coronarienne/traitement médicamenteux , Endoprothèses à élution de substances/effets indésirables , Études de suivi , Modèles logistiques , Infarctus du myocarde/étiologie , Revascularisation myocardique , Odds ratio , Paclitaxel/usage thérapeutique , Valeur prédictive des tests , Sirolimus/analogues et dérivés , Thrombose/étiologie , Résultat thérapeutiqueRÉSUMÉ
Introducción: La reducción de la reestenosis intrastent ha permitido una gran aceptación de los stents liberadores de drogas (DES). El objetivo de este trabajo ha sido evaluar nuestra experiencia clínica inicial con DES y compararla con aquellos que sólo recibieron BMS (stents no liberadores de drogas). Materiales y Métodos: Se compararon 71 pacientes tratados con DES (Cypher® = 32 o Taxus® = 39) con 903 pacientes tratados sólo con BMS. Además del análisis clínico y angiográfico detallado, se efectuó seguimiento clínico de a lo menos 6 meses. Resultados: Los pacientes tratados con DES con mayor frecuencia eran más complejos y tenían características clínicas y angiográficas desfavorables. Sin embargo, no hubo diferencias en la tasa de éxito angiográfico (100 vs. 99,2 por ciento) ni en las complicaciones isquémicas intrahospitalarias (1,3 vs. 0 por ciento). En el seguimiento los tratados con DES tuvieron menor recurrencia de la angina (8,7 vs. 19,0 por ciento), revascularización del vaso tratado (0 vs. 7,5 por ciento) y menos eventos isquémicos (4,4 por ciento vs. 14,6 por ciento). Conclusiones: A pesar de su empleo en pacientes con características clínicas y angiográficas desfavorables, los DES lograron un mejor resultado a largo plazo en comparación con los BMS.
Background: There has been considerable enthusiasm for drug eluting stents (DES) in coronary angioplasty due to the lower restenosis rate associated to their use. Aim: To compare clinical and angiographic results of DES implantation, compared to traditional bare metal stents (BMS) Methods: 71 patients who received DES (Cypher® = 32; Taxus® = 39) were compared to 903 patients who had received BMS. Detailed clinical and angiographic evaluation and 6 month follow up data were analyzed. T test and X2 analysis were used for comparisons. Results: Compared to the BMS group, the DES group had complex clinical (diabetes mellitus, family history, active smokers) and agiographic findings (lower ejection fraction, longer lesions) in a greater proportion of cases (p < 0.05 vs BMS). The immediate angiographic success rate did not differ between groups (100 percent vs 99.2 percent, respectively). Acute ischemic complications occurred in 1.3 percent in DES patients compared to 0 percent in BMS (pNS). At follow-up, angina recurrence (8.7 percent vs 19 percent, p < 0.043), need for revascularization (0 percent vs 7.5 percent, p < 0.02) and new ischemic events (4.4 percent vs 14.6 percent, p < 0.02) were lower in DES as compared to BMS patients. Conclusion: In spite of the greater clinical and angiographic complexity, patients with DES had better long term clinical results than patients who received BMS.
Sujet(s)
Humains , Mâle , Femelle , Adulte d'âge moyen , Angioplastie coronaire par ballonnet/méthodes , Sténose coronarienne/traitement médicamenteux , Sténose coronarienne , Endoprothèses , Évolution Clinique , Études de cohortes , Coronarographie , Études de suivi , Métaux , Études prospectives , Récidive , Resténose coronaire/prévention et contrôle , Résultat thérapeutiqueRÉSUMÉ
OBJETIVO: Avaliar a redução do volume de hiperplasia intimal após angioplastia com stents com sirolimus (Cypher®) comparados com os stents não-recobertos de estrutura metálica fina (Pixel®) em pacientes com vasos pequenos. MÉTODOS: Oitenta pacientes com doença arterial coronariana foram prospectivamente incluídos em duas séries consecutivas de tratamento, sendo a primeira empregando stents com sirolimus (50) e a segunda stents não-recobertos de estrutura metálica fina (30). RESULTADOS: Os resultados foram: menor porcentual de obstrução da prótese através do ultra-som intracoronário [5,0 por cento (EP = 0,77) x 39,0 por cento (EP = 4,72), p < 0,001], menor perda tardia intra-stent [0,25 mm (EP = 0,03) x 1,11 mm (EP = 0,13), p < 0,001] e no segmento do vaso [0,30 mm (EP = 0,04) x 0,83 mm (EP = 0,11), p < 0,001], e também menor reestenose intra-stent (0 por cento x 33,3 por cento, p < 0,001) e no segmento do vaso (4 por cento x 36,7 por cento, p < 0,001) com os stents com sirolimus. A sobrevivência livre de eventos foi de 96 por cento com os stents com sirolimus x 86,7 por cento com os stents não-recobertos (p = 0,190). CONCLUSÃO: Os pacientes com vasos de pequeno calibre após o implante de stents com sirolimus evoluem com menor hiperplasia intimal (menor porcentual de obstrução intra-stent e menor perda tardia) do que quando são utilizados stents não-recobertos de estrutura metálica fina. Isto resultou em redução significativa da reestenose angiográfica aos oito meses de evolução.